Sign in Create account

Eris Lifesciences Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ERIS BSE: 540596
₹1191.90
▼ -27.40 (-2.25%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
51/100
Moderate
Valuation
12/100
Expensive
Momentum
8/100
Bearish

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹16,517 Cr
PE (TTM)
84.7
Industry median 36.1 (152 companies)
Price to Book
4.2
PEG (TTM)
4.3
Institutions holding %
26.47%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
-10.4
Relative return vs Sector, qtr %
-17.6
Free Cash Flow
₹241 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-52.45%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
87.69%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-6.89%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-51.70%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-23.27%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.74
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.59
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
2.53
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
10.88%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
23.94%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
26.47%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
8.79%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
15.72%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
16.62%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • No Debt to equity is below 0.5 (0.59)
  • Yes Return on equity is 15% or more (16.6%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (16.9% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.2%
Low 1180.8000 · High 1226.3000
1W return
-6.1%
Low 1180.1000 · High 1293.0000
1M return
-8.1%
Low 1180.1000 · High 1362.0000
52W return
-26.6%
Low 1180.1000 · High 1740.0000
Lifetime High ₹1847.7000 (June 16, 2025)
Lifetime Low ₹362.1500 (March 24, 2020)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
1229.4
10D
1254.9
20D
1282.0
50D
1323.7
100D
1355.5
200D
1390.7

Delivery and volume

Day avg. delivery
47.7%
Week avg. delivery
58.0%
Month avg. delivery
59.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1199.67
Pivot
First resistance1218.53
Second resistance1245.17
Third resistance1264.03
First support1173.03
Second support1154.17
Third support1127.53
Day RSI23.0
Day MFI20.5
Day MACD-31.29
Day MACD signal-21.74

Beta

1M0.63
3M0.56
1Y0.58
3Y0.48

Price change analysis

↓ -8.1%
Over 1 Month
LowHigh
1180.101362.00
↓ -17.6%
Over 3 Months
LowHigh
1180.101499.00
↓ -9.0%
Over 6 Months
LowHigh
1180.101530.00
↓ -26.6%
Over 1 Year
LowHigh
1180.101740.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 84.7 (own history: 38.3–249.5)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹444 Cr
Net profit (June 30, 2026)
₹48 Cr
Basic EPS (June 30, 2026)
₹3.4900

Ranks #34 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter54.14%
  • Mutual funds18.88%
  • FII/FPI5.75%
  • Other DII1.84%
  • Public19.39%

Largest holders

NameCategoryShares %Shares
Amit Indubhusan BakshiPromoter42.3400%58674237
Lilac Investments LimitedPublic8.6300%11965882
Hdfc Small Cap FundPublic8.3300%11539105
Rajendrakumar Rambhai PatelPromoter4.2900%5939834
Inderjeet Singh NegiPromoter4.2900%5939833

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings increased from 53.92% to 54.14% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 6.39% to 5.75% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 18.22% to 18.88% in Jun 2026 qtr

24 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 61 insider trades, 9 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
18 Aug 2023 Sabyasachi Sharma Employee / designated person Sell 0 ₹0
6 Feb 2023 Amit Indubhushan Bakshi Promoter Buy 0 ₹0
23 Jan 2023 Amit Indubhushan Bakshi Director Buy 0 ₹0
15 Dec 2022 Amit Indubhushan Bakshi Director Buy 0 ₹0
8 Dec 2022 Amit Indubhushan Bakshi Promoter Buy 0 ₹0
21 Sep 2022 Vijaya Sampath Other Sell 0 ₹0
23 Jun 2022 Sabyasachi Sharma Other Buy 0 ₹0
23 Jun 2022 Chetan Doshi Other Buy 0 ₹0
26 May 2022 Chetan Doshi Other Sell 0 ₹0
23 May 2022 Sabyasachi Sharma Other Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 48 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
3 Oct 2024 RAKESH SHAH Bulk Sell 2,000,000 1350.0000 NSE
3 Oct 2024 MOTILAL OSWAL FINANCIAL SERVICES LIMITED Bulk Buy 2,079,000 1350.1800 NSE
22 Aug 2024 INFINITY PARTNERS Block Buy 9,886,882 1201.0000 NSE
22 Aug 2024 EMERALD INVESTMENTS LIMITED Block Sell 9,886,882 1201.0000 NSE
22 Aug 2024 INFINITY PARTNERS Bulk Buy 9,886,882 1201.0000 NSE
22 Aug 2024 EMERALD INVESTMENTS LIMITED Bulk Sell 9,886,882 1201.0000 NSE
15 Jul 2024 RAKESH SHAH Bulk Sell 2,000,000 1000.1200 NSE
15 Jul 2024 FRANKLIN TEMPLETON MUTUAL FUND Bulk Buy 1,094,201 1000.0400 NSE
31 Jan 2024 BHIKHALAL CHIMANLAL SHAH Bulk Sell 820,000 912.5000 NSE
31 Jan 2024 BHIKHALAL CHIMANLAL SHAH Bulk Sell 1,280,000 913.0900 BSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹7.21 per share
Dividend yield 0.60%
Ex-dateSubjectPer share (₹)Record date
29 May 2026 Interim Dividend - Rs 7.21 Per Share 7.2100 29 May 2026
13 Feb 2025 Interim Dividend - Rs 7.35 Per Share 7.3500 13 Feb 2025
11 Aug 2022 Interim Dividend- Rs 7.35 Per Share 7.3500 16 Aug 2022
5 Aug 2021 Interim Dividend - Rs 6.01 Per Share 6.0100 6 Aug 2021
13 Aug 2020 Interim Dividend - Rs 5.50 Per Share 5.5000 14 Aug 2020
19 Mar 2020 Interim Dividend - Rs 2.87 Per Share 2.8700 20 Mar 2020

Corporate Actions

Full history (15 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
17 Sep 2024OTHERAnnual General Meeting
15 Sep 2023OTHERAnnual General Meeting
23 Aug 2022OTHERAnnual General Meeting
23 Aug 2021OTHER Annual General Meeting
18 Sep 2020OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
29 Jul 2026 Financial Results Yes
20 May 2026 Financial Results/Dividend Yes
13 Feb 2026 Financial Results Yes
24 Nov 2025 Fund Raising —
12 Nov 2025 Financial Results Yes

Corporate Announcements

All 943 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Insider Trading / SAST Eris Lifesciences Ltd - 540596 - Closure of Trading Window
28 Sep 2026 Trading Window Eris Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Shareholders meeting Eris Lifesciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 25, 2026. Further, the company has informed the Exchange regarding voting results.
25 Sep 2026 Shareholders meeting Eris Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026
25 Sep 2026 AGM/EGM Eris Lifesciences Ltd - 540596 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
25 Sep 2026 AGM/EGM Eris Lifesciences Ltd - 540596 - Shareholder Meeting / Postal Ballot-Outcome of AGM
25 Sep 2026 AGM/EGM Eris Lifesciences Ltd - 540596 - Shareholder Meeting / Postal Ballot-Outcome of AGM
22 Sep 2026 Allotment of Securities Eris Lifesciences Limited has informed the Exchange regarding allotment of 155264 securities pursuant to ESOP/ESPS at its meeting held on September 22, 2026
21 Sep 2026 Appointment Eris Lifesciences Limited has informed the Exchange regarding Appointment of Mr as Non- Executive Independent Director of the company w.e.f. September 26, 2026.
21 Sep 2026 Company Update Eris Lifesciences Ltd - 540596 - Appointment Of Mr. Akhil Awasthi As An Additional Director (Non-Executive, Independent) Of The Company

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

  • Tight liquidity (Current Ratio 0.74)
  • Declining revenue YoY (-23.3%)
  • Declining profit YoY (-51.7%)

Opportunities

  • RSI in oversold territory (23.0) -- a technical rebound zone

Threats

  • PE above 35 (84.7) -- priced for continued strong execution
  • Down 26.6% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Part of: NIFTY 500

Frequently asked questions about Eris Lifesciences Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.